Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasm Metastasis 1Melanoma 1Limited Stage Small Cell Lung Cancer 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5liposomal doxorubicin 4Topotecan 3Cyclophosphamide 3pembrolizumab 2oregovomab 2olaparib 2niraparib 2fludarabine 2Nivolumab 2Drug Therapy 2trastuzumab deruxtecan 1rucaparib 1ribociclib 1palbociclib 1mirvetuximab soravtansine 1isoquercitrin 1irinotecan sucrosofate 1fludarabine phosphate 1denileukin diftitox 1anlotinib 1Tinzaparin 1Saline Solution 1Propranolol 1Preoperative Exercise 1Platinum 1Palliative Care 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Glucose × 90 days × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡